Ginkgo Bioworks (NYSE:DNA) and SaponiQx, a unit of Agenus (NASDAQ:AGEN) have received a multi-year contract worth up to $31M from the U.S. government to develop next-generation vaccine adjuvants, the ...
Gregory Moore does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
With the children of the company’s co-founders right up front, the Ginkgo Bioworks team rang the bell of the New York Stock Exchange this morning, taking the synthetic biology company public. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results